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The Role of p53 in Atherosclerosis
ABSTRACT
Although the role of the tumor suppressor gene p53 is well known in cancer, recent
studies have highlighted a fundamental role for p53 in regulating cells in the advanced
atherosclerotic plaque, the major cause of heart attacks and stroke. In particular, p53 is
activated in the complex environment of the plaque, in part by DNA damage within the
lesion, and regulates growth arrest, cell senescence and apoptosis of vascular smooth
muscle cells (VSMCs). The role of endogenous p53 has been determined using p53
knockout in mice developing advanced atherosclerosis, using bone marrow transplant to
separate effects on blood cells from vessel wall cells. These studies have produced appar-
ently contradictory and surprising results. In particular, recent studies have identified a
role for endogenous p53 in protection of VSMCs from apoptosis, trans-differentiation of
bone marrow stromal cells into VSMCs in atherosclerosis, and altering the mode of cell
death in the plaque.
INTRODUCTION
Heart attacks and stroke are the commonest cause of death in the Western world, and
by 2020 are predicted to be the commonest cause of death worldwide. Both diseases are
clinical manifestations of atherosclerosis, the thickening of the innermost layer of the
artery wall. Atherosclerotic plaques consist of an accumulation of vascular smooth muscle
cells (VSMCs), inflammatory cells (macrophages, T lymphocytes, dendritic cells and mast
cells) underlying a dysfunctional endothelium, together with extracellular lipid, collagen
and matrix. Recruitment of circulating inflammatory cells is an early event in atheroscle-
rosis, which triggers reactive proliferation and migration of VSMCs of the vessel wall.
There is also increasing evidence that circulating cells can transdifferentiate into VSMCs
that comprise native atherosclerotic plaques and a variety of other vascular pathologies.1,2
Most atherosclerosis is clinically silent, and consequences of atherosclerosis rarely occur
before the development of advanced lesions. Many advanced plaques comprise a
VSMC-rich fibrous cap overlying a lipid and macrophage rich necrotic core, and it is the
relative proportion of these components that determine the clinical manifestations of the
plaque. For example, unstable plaques (that are prone to rupture) contain a higher proportion
of inflammatory cells and lipid, and a lower proportion of VSMCs than stable lesions. In
particular, the fibrous cap of advanced plaques is thinned from loss of VSMCs, and these
thin-cap fibroatheromata are the commonest lesions that rupture to produce fatal heart
attacks.
p53 expression and phosphorylation is increased in advanced human plaques, in
association with oxidative DNA damage and activation of DNA repair pathways.3-5 The
inability to find p53 mutations in atherosclerosis3 together with colocalization with
MDM2 and p214,6 suggests that detected p53 is wild type and is transcriptionally active.
Thus, the major effects of p53 in atherosclerosis are likely to be due to augmentation of
wild type p53 activity, including growth arrest, senescence and apoptosis. Indeed, plaque
VSMCs show impaired proliferation compared with cells from normal vessels and early
senescence,7 coupled with expression of typical pRB-mediated growth arrest proteins,
including the p53 target p21. In vitro, inhibition of p53 and pRB bypasses the growth
arrest and cell senescence of plaque VSMCs, demonstrating that premature senescence of
human plaque VSMCs is determined by pRB and p53.7 In vitro, plaque VSMCs have
increased sensitivity to p53-induced apoptosis.8 This is partly due to impaired protection
in plaque VSMCs, but p53 can also sensitize cells to death receptor signaling.9
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Whilst what p53 does in vitro in VSMCs appears straight-
forward, and is similar to other mesenchymal cells, the role of p53 in
VSMC proliferation and apoptosis in atherosclerosis is more contro-
versial. p53 expression is negatively correlated with markers of cell
proliferation in human atherosclerosis,4 suggesting that p53 inhibits
cell proliferation in vivo. Indeed, adenovirus expression of p53
(Ad-p53) reduces cell proliferation in the rat carotid artery10 or
migration in the human saphenous vein11 and conversely, antisense
oligonucleotides to p53 increase proliferation.12 p53 expression is
associated with increased apoptosis in vivo and in vitro.13-15 Ad-p53
induces VSMC apoptosis and plaque rupture in a collar model of
atherosclerosis in ApoE knockout mice that develop accelerated
atherosclerosis,16 and apoptosis in human saphenous vein intima
and media.11
These studies all suggest that p53 inhibits cell proliferation and
promotes VSMC apoptosis in atherosclerosis. However, direct in
vivo evidence from separate studies is contradictory, and in particu-
lar, the effect of p53 deficiency on different cell types is unclear.17-19
Mice deficient for p53 crossed onto a variety of atherosclerosis-prone
mice (ApoE-/-, ApoE*3-Leiden, or LDL-R-/-) develop accelerated
atherosclerosis compared with p53+/+ mice. However, two studies
from the same group found that p53-/- mice show increased cell
proliferation but no change in apoptosis,17,19 whereas the third
study demonstrated reduced apoptosis, but no change in cell prolif-
eration.18 Although these studies have demonstrated effects of p53
on macrophages by bone marrow transplant,18,19 none of the studies
identified the lineage of the proliferating/dying cells. In addition,
none of the studies examined the specific role of p53 knockout in
VSMCs, as transplants were performed of p53+/+ or p53-/- cells into
p53+/+ mice, so that VSMCs derived from the vessel wall were all
p53+/+. Finally, the effects of p53 were not examined in more
advanced lesions, where p53 is more expressed than in early plaques.
This situation appears to have been clarified by two recent studies.
In the first, we examined atherosclerosis in advanced lesions of
p53-/-/ApoE-/- mice vs. ApoE-/- mice expressing wild type p53. Cell
lineage of proliferating and apoptotic cells was examined. p53-/-/
ApoE-/- mice showed increased aortic plaque formation, with
increased rates of cell proliferation and reduced rates of apoptosis in
brachiocephalic artery plaques. Although most proliferating cells
were monocyte/macrophages, apoptotic cells were both vascular
smooth muscle cells (VSMCs) and macrophages. Transplant of
p53+/+ bone marrow to p53-/-/ApoE-/- mice reduced aortic plaque
formation and cell proliferation in brachiocephalic plaques, but also
markedly reduced apoptosis. These findings indicate that the major
effect of endogenous p53 in atherosclerosis is to limit proliferation,
but also protect against apoptosis.
We studied VSMCs in culture to examine this potential
anti-apoptotic effect. Indeed, p53-/- VSMCs showed enhanced
apoptosis following serum deprivation, UV irradiation and etopo-
side treatment, and was associated with activation of DNA damage
pathways. Reexpression of p53 using a conditional allele rescued
apoptosis and inhibited the DNA damage response. We also exam-
ined the ability of p53 to alter the trans-differentiation of bone
marrow stromal cells into cells that resemble VSMCs. Endogenous
p53 and Atherosclerosis
Figure 1. Schematic of an advanced atherosclerotic plaque showing a VSMC-rich fibrous cap separating a lipid rich necrotic core from the vessel lumen.
Plaque macrophages are indicated as red cells in the shoulder region of the plaque, the most frequent site of plaque rupture. Whilst endogenous p53 pro-
tects VSMCs from apoptosis, in part by promoting DNA repair, increased p53 above basal levels induces apoptosis. Endogenous p53 also inhibits trans-
differentiation of bone marrow-derived stromal cells into VSMCs. In contrast, endogenous and increased p53 promote macrophages apoptosis; loss of p53
in macrophages may lead to secondary necrosis.
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p53 inhibited the trans-differentiation of stromal cells, and also
inhibited their apoptosis. In contrast, p53-/- macrophages showed
the predicted resistance to apoptosis compared with p53+/+
macrophages.
More recently, macrophage specific p53 deficiency has been
achieved using cre-lox technology, to examine the role of endoge-
nous p53 in atherosclerosis in ApoE-/- mice.20 Surprisingly, p53
deficiency in macrophages reduced apoptosis but increased necrosis
in these lesions.
These findings identify novel anti-apoptotic functions of endoge-
nous p53 in VSMCs and stromal cells that differentiate into
VSMCs. The protective effect of endogenous p53 in fibroblasts has
been noted before, and mapped to the C-terminal 38 amino
acids.21,22 Although this activity did not require transcriptional
activity, its mechanism is currently unclear. We find that endogenous
p53 inhibits DNA damage signaling in VSMCs, consistent with
published studies that demonstrate a role in repair of single strand
breaks, nucleotide excision repair and homologous recombination.23-26
In addition, p53 protects the genome from oxidation by reactive
oxygen species (ROS), a major cause of DNA damage in atheroscle-
rosis. In the absence of severe stresses, relatively low levels of p53 are
sufficient for upregulation of several genes with antioxidant products,
associated with a decrease in intracellular ROS.27 Downregulation of
p53 results in excessive oxidation of DNA,27 which may trigger the
activation of the DNA damage response pathways we observe in
p53-/- cells, ultimately promoting apoptosis. p53 can also prevent
the release of pro-apoptotic molecules from the mitochondria, in
part by suppressing JNK activity.28 Our studies also suggest that p53
regulates the differentiation of stromal cells into VSMCs, at least in
vitro. Again, the mechanism of this effect is unclear, and it remains
possible that it is secondary to the enhanced ability of stromal cells
from p53-/- mice to survive and proliferate in culture in conditions
that promote differentiation.
At last it appears we can draw some firm conclusions from these
studies (Fig. 1). First, global deficiency of p53 increases atheroscle-
rosis formation. This appears to be due to an increase in proliferation
of VSMCs. Secondly, p53 deficiency protects macrophages from
apoptosis, but may promote macrophage necrosis, so that overall
death rates of macrophages may not change. Thirdly, p53 deficiency
in VSMCs appears to be actively protective; this may be due in part
to its ability to promote DNA repair and turn off the response to
DNA damage.
In conclusion, it is clear that in a complex tissue such as the
atherosclerotic plaque, the effects of both loss of p53 and p53 over-
expression depend upon the cell type under study. We cannot simply
extrapolate the results from tumor cell lines which contain multiple
mutations (such as oncogene activation) in addition to loss of p53,
or embryonic fibroblasts, which have proliferative potential far above
adult human mesenchymal cells, to explain how p53 functions in
human atherosclerosis. p53 can promote growth arrest, cell senes-
cence and apoptosis in atherosclerosis, in line with its conventional
properties. However, endogenous p53 can also regulate trans-differ-
entiation, protect against apoptosis and alter the mode of cell death
within the plaque. Only by selectively altering p53 expression in
different components of the plaque do these more subtle activities
emerge.
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